4.5 Article

Supplementation with Iron in Pulmonary Arterial Hypertension Two Randomized Crossover Trials

Journal

ANNALS OF THE AMERICAN THORACIC SOCIETY
Volume 18, Issue 6, Pages 981-988

Publisher

AMER THORACIC SOC
DOI: 10.1513/AnnalsATS.202009-1131OC

Keywords

pulmonary arterial hypertension; iron; ferric carboxymaltose; iron dextran; exercise capacity

Funding

  1. British Heart Foundation [RG/10/16/28575]

Ask authors/readers for more resources

Studies on parenteral iron replacement in PAH patients show that iron complexes can improve iron status, but no significant effects on exercise capacity or cardiopulmonary hemodynamics were observed within 12 weeks.
Rationale: Iron deficiency, in the absence of anemia, is common in patients with idiopathic and heritable pulmonary arterial hypertension (PAH) and is associated with a worse clinical outcome. Oral iron absorption may be impeded by elevated circulating hepcidin concentrations. The safety and benefit of parenteral iron replacement in this patient population is unclear. Objectives: To evaluate the safety and efficacy of parenteral iron replacement in PAH. Methods: In two randomized, double-blind, placebo-controlled 12-week crossover studies, 39 patients in Europe received a single infusion of ferric carboxymaltose (Ferinject) (1,000 mg or 15 mg/kg if weight <66.7 kg) or saline as placebo, and 17 patients in China received iron dextran (Cosmofer) (20 mg iron/kg body weight) or saline placebo. All patients had idiopathic or heritable PAH and iron deficiency at entry as defined by a serum ferritin <37 mu g/L or iron <10.3 mu mol/L or transferrin saturations <16.4%. Results: Both iron treatments were well tolerated and improved iron status. Analyzed separately and combined, there was no effect on any measure of exercise capacity (using cardiopulmonary exercise testing or 6-minute walk test) or cardiopulmonary hemodynamics, as assessed by right heart catheterization, cardiac magnetic resonance, or plasma NT-proBNP (N-terminal-pro hormone brain natriuretic peptide) at 12 weeks. Conclusions: Iron repletion by administration of a slow-release iron preparation as a single infusion to patients with PAH with iron deficiency without overt anemia was well tolerated but provided no significant clinical benefit at 12 weeks.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available